Celyad SA (CYAD): Price and Financial Metrics
CYAD Price/Volume Stats
| Current price | $0.47 | 52-week high | $3.07 |
| Prev. close | $0.53 | 52-week low | $0.46 |
| Day low | $0.47 | Volume | 49,000 |
| Day high | $0.53 | Avg. volume | 1,137,243 |
| 50-day MA | $0.77 | Dividend yield | N/A |
| 200-day MA | $1.19 | Market Cap | 10.62M |
CYAD Stock Price Chart Interactive Chart >
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Latest CYAD News From Around the Web
Below are the latest news stories about CELYAD ONCOLOGY SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.
Celyad Oncology Announces Receipt of Nasdaq Delisting NoticeMONT-SAINT-GUIBERT, Belgium, May 15, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. |
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From NasdaqMONT-SAINT-GUIBERT, Belgium, May 05, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares ("ADSs") from the Nasdaq Global Market, termination of its American Depositary Receipt ("ADR") facility and deregistration w |
Celyad Oncology Reports First Quarter 2023 Financial Results and Recent Business HighlightsMONT-SAINT-GUIBERT, Belgium, May 05, 2023--PR Q1 results |
Celyad Oncology Announces Receipt of Nasdaq Initial Notification on ADS Bid PriceMONT-SAINT-GUIBERT, Belgium, April 24, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the "Bid Price Notice") on April 19th, 2023 from The Nasdaq Stock Market ("Nasdaq") informing the Company that the minimum closing bid price per share of its American Depositary Shares representing ordinary shares ("ADSs") was below $1.00 for a pe |
Celyad Oncology announces receipt of Nasdaq noticeMONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letter”) on March 31, 2023 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that |
CYAD Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -27.27% |
| 3-year | -92.70% |
| 5-year | -97.67% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -86.53% |
| 2021 | -53.08% |
| 2020 | -25.14% |
| 2019 | -42.62% |
Continue Researching CYAD
Want to see what other sources are saying about Celyad Sa's financials and stock price? Try the links below:Celyad Sa (CYAD) Stock Price | Nasdaq
Celyad Sa (CYAD) Stock Quote, History and News - Yahoo Finance
Celyad Sa (CYAD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...